Last update Sept. 3, 2017
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Alogliptin Benzoate is also known as Alogliptin.
Alogliptin Benzoate in other languages or writings:
Alogliptin Benzoate belongs to this group or family:
Main tradenames from several countries containing Alogliptin Benzoate in its composition:
|Oral Bioavail.||70 - 100||%|
|Protein Binding||20 - 30||%|
|VD||4.3 - 6||l/Kg|
|Tmax||1 - 2||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the GLP-1 and GIP intestinal hormones involved in the physiological regulation of glucose, which are activated by eating (EMA 2016, Baetta 2011, Scheen 2011).
Administered orally, once a day.
Common side effects are upper respiratory tract infections, urinary tract infections, gastrointestinal disorders, rash and headaches (EMA, 2016). Low risk of hypoglycemia in monotherapy (EMA, 2015, Scheen 2011).
Doses up to 16 times higher than normal for 2 weeks did not produce side effects (EMA, 2015).
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2015, Scheen 2011): low molecular weight, low percentage of binding to plasma proteins and very long half-life) make it likely it will pass into breast milk in concentrations that could be significant.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
Among the antidiabetics of this same group, saxagliptin and vildagliptin would be preferable due to their short half-life (less than 3 hours).
See below the information of these related products: